Roivant Sciences (NASDAQ:ROIV) Stock Acquired Rep. Lisa C. McClain

Key Points

• Representative Lisa C. McClain purchased between $1,001 and $15,000 in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) on June 17th, as disclosed in a filing.
• Roivant Sciences recently reported a net loss with an earnings per share of ($0.31), which missed analyst expectations of ($0.16).
• Goldman Sachs upgraded Roivant Sciences to a "strong-buy" rating with a target price of $19.00, amid a generally positive outlook from analysts.

Representative Lisa C. McClain (R-Michigan) recently bought shares of Roivant Sciences Ltd. NASDAQ: ROIV. In a filing disclosed on August 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in Roivant Sciences stock on June 17th. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Autoliv NYSE: ALV on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Arthur J. Gallagher & Co. NYSE: AJG on 8/4/2025.
• Sold $1,001 - $15,000 in shares of SAP NYSE: SAP on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of XPO NYSE: XPO on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Lithia Motors NYSE: LAD on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Sanofi NASDAQ: SNY on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Waters NYSE: WAT on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Group 1 Automotive NYSE: GPI on 7/22/2025.

Roivant Sciences Stock Up 1.7%

ROIV stock traded up $0.20 during trading on Tuesday, hitting $11.84. 5,949,919 shares of the company's stock traded hands, compared to its average volume of 4,428,611. The firm has a market capitalization of $8.09 billion, a P/E ratio of -16.91 and a beta of 1.15. The business has a fifty day simple moving average of $11.46 and a two-hundred day simple moving average of $10.93. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $13.06.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its quarterly earnings data on Thursday, May 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.15). The business had revenue of $7.57 million for the quarter, compared to analysts' expectations of $62.17 million. Roivant Sciences had a negative net margin of 2,111.79% and a negative return on equity of 15.90%. During the same period in the previous year, the business earned ($0.23) earnings per share. On average, equities research analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Institutional Trading of Roivant Sciences

Large investors have recently bought and sold shares of the business. Parallel Advisors LLC boosted its holdings in Roivant Sciences by 80.5% in the 1st quarter. Parallel Advisors LLC now owns 2,485 shares of the company's stock valued at $25,000 after purchasing an additional 1,108 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Roivant Sciences by 478.6% in the 4th quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock worth $28,000 after acquiring an additional 1,948 shares during the last quarter. CWM LLC increased its stake in Roivant Sciences by 44.6% during the 2nd quarter. CWM LLC now owns 2,984 shares of the company's stock worth $34,000 after buying an additional 920 shares during the period. UMB Bank n.a. increased its stake in Roivant Sciences by 112.7% during the 1st quarter. UMB Bank n.a. now owns 4,143 shares of the company's stock worth $42,000 after buying an additional 2,195 shares during the period. Finally, Fifth Third Bancorp increased its stake in Roivant Sciences by 59.3% during the 1st quarter. Fifth Third Bancorp now owns 5,118 shares of the company's stock worth $52,000 after buying an additional 1,905 shares during the period. Hedge funds and other institutional investors own 64.76% of the company's stock.

Insiders Place Their Bets

In related news, major shareholder Vivek Ramaswamy sold 577,007 shares of Roivant Sciences stock in a transaction on Friday, June 20th. The shares were sold at an average price of $11.46, for a total transaction of $6,612,500.22. Following the sale, the insider directly owned 37,284,108 shares in the company, valued at $427,275,877.68. This trade represents a 1.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Eric Venker sold 100,000 shares of the firm's stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $11.72, for a total transaction of $1,172,000.00. Following the transaction, the chief executive officer directly owned 1,653,585 shares in the company, valued at $19,380,016.20. The trade was a 5.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,190,503 shares of company stock worth $36,163,546 over the last 90 days. Company insiders own 10.80% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on ROIV shares. The Goldman Sachs Group upgraded shares of Roivant Sciences to a "strong-buy" rating and set a $19.00 target price for the company in a research note on Thursday, July 10th. HC Wainwright restated a "buy" rating and set a $18.00 target price on shares of Roivant Sciences in a research report on Wednesday, June 18th. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Roivant Sciences currently has an average rating of "Buy" and a consensus target price of $16.50.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.